8-K: IN8bio Regains Nasdaq Compliance, Resolving Minimum Bid Price Issue

IN8bio, Inc. announced it has received formal notification from The Nasdaq Stock Market LLC confirming compliance with the minimum bid price requirement, effectively closing the matter.

Summary

• IN8bio, Inc. received a formal notification from The Nasdaq Stock Market LLC on June 24, 2025.
• The notification confirmed that IN8bio has regained compliance with Nasdaq Listing Rule 5550(a)(2).
• This rule requires listed companies to maintain a minimum bid price of at least $1.00 per share.
• Nasdaq has confirmed that the matter regarding the minimum bid price compliance is now closed.

Sentiment

Score: 8

Explanation: The document reports the successful resolution of a significant compliance issue (potential delisting), which is a clear positive for the company's stability and investor confidence.

Positives

• IN8bio has successfully regained compliance with Nasdaq's minimum bid price requirement.
• The formal notification from Nasdaq confirms the resolution of the compliance issue, removing the threat of delisting due to this specific rule.
• The matter is officially closed by Nasdaq, providing certainty regarding the company's listing status.

Risks

• The risk of delisting from The Nasdaq Stock Market LLC due to non-compliance with the minimum bid price rule (5550(a)(2)) has been resolved and is now closed.

Future Outlook

The document does not contain any forward-looking statements or guidance beyond the resolution of the Nasdaq compliance matter.

Industry Context

This announcement pertains to a standard regulatory compliance matter for a publicly traded company, specifically addressing a listing requirement on The Nasdaq Stock Market. While not directly related to broader industry trends in biotechnology, maintaining listing compliance is fundamental for companies in all sectors to access capital markets and maintain investor confidence.

Stakeholder Impact

• Shareholders: The resolution of the Nasdaq compliance issue removes the risk of delisting due to the minimum bid price, which is positive for shareholder value and liquidity.

Key Dates

Recommendation

Keywords

IN8bio, Nasdaq, Compliance, Minimum Bid Price, 8-K, Listing Rule 5550(a)(2), Biotechnology